OnCo
companiesCompany

CG Oncology

CG Oncology developed cretostimogene, the oncolytic virus for early bladder cancer, and is filing for approval in 2026.

BOND-003 (BCG-unresponsive CIS), PIVOT-006 (intermediate-risk), CORE-008 (BCG-naive). IPO 2024.

Headquarters
Irvine, CA, US
Type
biotech · CGON

Products

1top
Phase 3Oncolytic adenovirus (intravesical)
Cretostimogene grenadenorepvec

Cretostimogene is a virus engineered to multiply only in bladder cancer cells with a broken RB pathway, instilled into the bladder. It cleared carcinoma in situ in 75% of BCG-unresponsive patients.

Connected

4top

cancers

1
Bladder & urothelial cancer

fronts

1
Immunotherapy

drugs

1
Phase 3Oncolytic adenovirus (intravesical)
Cretostimogene grenadenorepvec

ideas

1
Oncolytic viruses that make interleukin-12 only inside the tumour